Health
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.
- Published
- (4 days ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 19-word snippet. The full article is at the source.
More from STAT News and around the same time
STAT+: Roche gets a lung cancer win with its KRAS drug divarasibOne of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.STAT+: Nonprofit Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chainThe deal would make the Catholic system one of the largest operators of outpatient surgery centers.STAT+: HHS relaxes security, transparency rules for health record software used by hospitalsThe Trump administration removed several security, privacy and transparency requirements for vendors of EHR software.STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmaciesA House lawmaker is investigating whether the three largest PMS targeted independent pharmacies withretaliatory audits.STAT+: GSK sees its return to cancer starting to pay offA decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancerA Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancerThis page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
